Navigation Links
Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer
Date:4/19/2009

to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit www.dendreon.com.

Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties surrounding the efficacy of PROVENGE to treat men suffering from prostate cancer, risks and uncertainties surrounding the presentation of data to the FDA and approval of product applications by the FDA and risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such differences include risks related to our limited operating history, risks associated with completing our clinical trials, the risk that the safety and/or efficacy results of existing clinical trials or from additional clinical trials for PROVENGE will not support approval for a biologics license, the risk that the FDA may interpret data differently than we do or require more data or a more rigorous analysis of data than expected, the risk that the FDA will not approve a product for which a biologics license has been applied, the risk that the results of a clinical trial for PROVENGE or other product may not be indicative of results obtained in a later clinical trial, risks that we may lack the financial resources and access to capital to fund required clinical trials or commercialization of PROVENGE, our dependence on the efforts of third parties, and our dependence on intellectual property. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securiti
'/>"/>

SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Reports Fourth Quarter and 2008 Year End Financial Results
2. Dendreon Announces Webcast Presentation at Eleventh Annual BIO CEO & Investor Conference
3. Dendreon Announces Webcast Presentation at 27th Annual J.P. Morgan Healthcare Conference
4. Dendreon Reports Third Quarter 2008 Financial Results
5. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
6. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
7. Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
8. Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
9. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
10. Dendreon Reports First Quarter 2008 Financial Results
11. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014 LayerBio is an MIT spin-off ... care. The National Eye Institute (NEI) at the National ... I SBIR grant to develop a drug-eluting intraocular lens ... common cause of vision loss in people over age ... to Dr. Ken Mandell, LayerBio’s Founder and CEO, "There ...
(Date:12/19/2014)... iLab Solutions, the global leader in core ... as the new Director of Institutional Implementations and Sarah ... two new leadership positions were created to support iLab’s ... iLab continues to meet the needs of its growing ... has been deployed at over 450 core facilities across ...
(Date:12/19/2014)... With only 2 weeks left of 2014, ... Biohit products . The product specials include Buy 1 ... Trade-in Program, and free pipette tips. , Sartorius mLINE ... world. They are ideal for lab technicians performing long ... ,     Full volume range of 0.1 uL to 10 ...
(Date:12/19/2014)... , Dec. 18, 2014   ISN has ... Safety Performance Indicators publication series. With data ... activity reported in 2013 within its online contractor management ... safety key performance indicator (KPI) statistics. ... U.S. publication is available in two industry ...
Breaking Biology Technology:LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2Major Pipette Distributor Pipette.com Announces Sartorius Year End Specials 2ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 2ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 3
... have unlocked the physics of the perfect pizza toss ... of micro motors thinner that a human hair. , ... Associate Professor James Friend and Senior Lecturer Leslie Yeo, ... from Monash,s Micro/Nanophysics Research Laboratory, then calculated how best ...
... Encorium Group, Inc. (Nasdaq: ENCO ) ... that provides design, development, and management capabilities for clinical ... leading pharmaceutical companies, today announced the signing of approximately ... new business contracts and repeat business to be conducted ...
... ("Sinobiopharma ", or "the Company") (OTC Bulletin Board: SNBP) ... to seven key patents from Company CEO Dr. Lequn ... significantly enhance Sinobiopharma,s ability to execute on its mission ... are for the following:, , ...
Cached Biology Technology:Pizza tossing art unlocks secrets of tiny motors 2Encorium Group Signs Approximately $2.0 Million of New Business Contracts 2Encorium Group Signs Approximately $2.0 Million of New Business Contracts 3Sinobiopharma Secures Rights to Seven Key Patents 2
(Date:12/17/2014)... DUBLIN , Dec. 16, 2014 Research ... announced the addition of the "Global Chemical ... http://photos.prnewswire.com/prnh/20130307/600769 ... is the increasing demand for medical sensors in ... patient data for quick and correct diagnosis during ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has ... in the APAC Region 2015-2019"  report to their ... in this market is advances in technology. With ... upgrade biometric solutions to the latest standard that ...
(Date:12/11/2014)... PAUL, Minn. , Dec. 10, 2014 /PRNewswire/ ... wireless physiologic monitoring, has released a new series ... needs of preclinical toxicology researchers. M series, part ... help toxicologists collect the best possible physiologic data ... Adding functional endpoints to toxicology studies ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
... Vision, Inc.,(OTC Bulletin Board: INVI), a leading global ... has received an order for the,Company,s SharpEye(TM) system ... large,computer manufacturer. The SharpEye product provides analysis of ... quality in the manufacturing,process, and the system will ...
... Corporate Safe Specialists (CSS),announces an addition to its ... as National Account Manager., (Photo: http://www.newscom.com/cgi-bin/prnh/20080114/AQM106 ... Currey, Sales Manager of the Company, stated, "the ... accelerate the growth we,ve seen in,networked safe sales. ...
... STATION A specially developed carrot has been produced to ... A&M AgriLifes Vegetable and Fruit Improvement Center studied the calcium ... net increase in calcium absorption. The research, which was done ... carrot to the diet can help prevent such diseases as ...
Cached Biology News:Integral Vision, Inc. Announces SharpEye(TM) Order From New Customer 2Corporate Safe Specialists Announces Addition to Sales Team 2Got carrots? Vegetables may have bone to pick as calcium providers 2
Polyclonal Antibody to Coronin / CORO1C This antibody was developed against synthetic peptides corresponding to amino acids 407-420 of human CORO1C....
... Tyrosine Hydroxylase (Ser40) Polyclonal Antibody ... against synthetic phosphopeptide corresponding to ... phospho-Ser40 of rat Tyrosine Hydroxylase ... by sequential chromatography on phospho- ...
Monoclonal Antibody to GLP Immunogen: Ni-NTA purified truncated recombinant GLP expressed in E. Coli strain BL21 (DE3)...
Biotin anti-human CD164...
Biology Products: